TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07801508: A Phase I, Open Label Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07801508 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07801508 Rescue Dossier →